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CNVs conferring risk of autism or
schizophrenia affect cognition in controls
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Sunna Arnarsdottir1,3, Gyda Bjornsdottir1, G. Bragi Walters1, Gudrun A. Jonsdottir1, Orla M. Doyle4, Heike Tost2, Oliver Grimm2,
Solveig Kristjansdottir1, Heimir Snorrason1, Solveig R. Davidsdottir3, Larus J. Gudmundsson1, Gudbjorn F. Jonsson1,
Berglind Stefansdottir1, Isafold Helgadottir3, Magnus Haraldsson3,5, Birna Jonsdottir6, Johan H. Thygesen7, Adam J. Schwarz8,
Michael Didriksen9, Tine B. Stensbøl9, Michael Brammer4, Shitij Kapur4, Jonas G. Halldorsson5, Stefan Hreidarsson10,
Evald Saemundsen5,10, Engilbert Sigurdsson3,5 & Kari Stefansson1
In a small fraction of patientswith schizophrenia or autism, alleles of copy-number variants (CNVs) in their genomes are
probably the strongest factors contributing to the pathogenesis of the disease. These CNVsmay provide an entry point for
investigations into the mechanisms of brain function and dysfunction alike. They are not fully penetrant and offer an
opportunity to study their effects separate from that of manifest disease. Here we show in an Icelandic sample that a few
of the CNVs clearly alter fecundity (measured as the number of children by age 45). Furthermore, we use various tests of
cognitive function to demonstrate that control subjects carrying the CNVs perform at a level that is between that of
schizophrenia patients and population controls. The CNVs do not all affect the same cognitive domains, hence the
cognitive deficits that drive or accompany the pathogenesis vary from one CNV to another. Controls carrying the
chromosome 15q11.2 deletion between breakpoints 1 and 2 (15q11.2(BP1-BP2) deletion) have a history of dyslexia and
dyscalculia, even after adjusting for IQ in the analysis, and the CNVonly confers modest effects on other cognitive traits.
The 15q11.2(BP1-BP2) deletion affects brain structure in apattern consistentwith both that observedduring first-episode
psychosis in schizophrenia and that of structural correlates in dyslexia.
Little information is available on whether or how rare CNVs confer-
ring high risk of schizophrenia and/or autism affect physiologic func-
tionof otherwise normal brains.Asnoneof theseCNVshitherto described
are fully penetrant for the diseases, and both schizophrenia and autism
affect cognition,we aimed to examine the possibility that theCNVs affect
cognition in control carriers, those who do not suffer either disease or
intellectual disability. We based our selection of CNVs on a literature
search for CNVs associatedwith schizophrenia and/or autism (‘neuro-
psychiatric CNVs’); this search produced 26 CNV alleles (Supplemen-
tary Table 1)1–3. These CNV alleles are rare, found in 0.002% to 0.2%
frequency, and cumulatively in 1.16% of our sample of 101,655 geno-
typed subjects, representing approximately one-third of the Icelandic
population (Supplementary Tables 1 and 2).
We used the subset of genotyped subjects born before 1968, without
excluding patients, to examine the association of each neuropsychia-
tric CNV with reproductive outcome (‘fecundity’), defined simply as
the number of children each subject had by age 45. After correction for
multiple comparisons, three neuropsychiatric CNVswere significantly
associatedwith fecundity (Table 1). Subjects carrying the 16p11.2 dele-
tionor the 22q11.21 duplication show reduced fecundity,with the effect
inmales significantly greater than in females (P5 0.0083 andP5 0.029
for thedifference in effect by sex for the 16p11.2 deletion and the 22q11.21
duplication, respectively). In contrast, individuals carrying the 16p12.1
deletion have more children than do controls (Table 1). Those with
deletions at 15q11.2(BP1-BP2) show a nominally significant reduction
in fecundity (Table 1). Consistentwith previous reports4, schizophrenia
patients show a large decrease in fecundity, with a more pronounced
reduction in males (P5 9.53 10225 for the difference in effect by sex)
(Table 1).
We recruitedneuropsychiatricCNVcontrol carriers, controls carrying
other CNVs not known to be associated with schizophrenia or autism
(‘otherCNVs’), controlswithout largeCNVs, and schizophreniapatients.
All recruited subjects (Supplementary Table 2 and Supplementary Fig. 1)
were administered a battery of neuropsychological tests (seeMethods),
the mini international neuropsychiatric interview (MINI)5 and the
general assessment of function scale (GAF)6.
The neuropsychiatric CNVs as a class
We found that the GAF score is 0.70 standard deviations (s.d.) lower
in the group of neuropsychiatric CNV control carriers than in popu-
lation controls (P5 2.23 10212). Based on MINIs, anxiety and sub-
stance abuse prevalences in the neuropsychiatric CNV control group
are similar to those of controls (P5 0.27 and0.36, respectively), however,
depression and suicidal ideation aremore common (odds ratio5 2.86,
P5 0.0017, and odds ratio5 2.20, P5 0.011, respectively). The other
CNVs have GAF scores 0.18 s.d. lower than population controls
(P5 0.0098), but donot differ significantly fromcontrols inprevalence
of phenotypes assessed by theMINI (P5 0.22, 0.90, 0.97 and 0.097, for
depression, suicidal ideation, anxiety and substance abuse, respectively).
Neurocognitive deficits, or heritable neurocognitive traits, are seen
in those at risk of schizophrenia and in unaffected family members7,8.
They typically distinguish patients with schizophrenia from controls
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with an effect size of approximately one s.d. (ref. 9). The cognitive
deficits seen in first-degree relatives of schizophrenia patients indicate
that they are partly independent of the clinical state10 and are likely to
persist in psychotic patients, at least in a milder form, even if a com-
plete remission would be achieved. All subjects were administered
tests for cognitive profiling that measure functions previously shown
to be impaired in schizophrenia patients, including attention, spatial
working memory, logical memory, executive function, cognitive flex-
ibility, language and processing speed (see Methods). On all tests, the
schizophrenia patients performed worse than population controls
(Fig. 1a and SupplementaryTable 3a). The neuropsychiatricCNVcontrol
carriers performedat a level between that of schizophrenia patients and
population controls, whereas the controls carrying other CNVs per-
formed in line with population controls (Fig. 1a and Supplementary
Table 3a). For all the tests, the association is much weaker when IQ is
taken into account (Fig. 1b and Supplementary Table 3b). This is not
surprising as the cognitive testsmeasure attributes that contribute to IQ.
Scores on the adult reading history questionnaire (ARHQ)11,12 and
adultmathematical history questionnaire (AMHQ) questionnaires (see
Methods), designed to detect a history of reading and mathematics
learning difficulties indicative of dyslexia and dyscalculia, separate the
control neuropsychiatric CNV carriers from population controls with
an effect of 0.50 s.d. (P5 3.13 1026) and 0.55 s.d. (P5 2.53 1027),
respectively (Fig. 1a).ARHQandAMHQscores for the carriers of other
CNVs are not significantly different from those of population controls
(P5 0.98 and 0.17, respectively).
Table 1 | Fecundity of neuropsychiatric CNV carriers and schizophrenia patients based on individuals born before 1968
CNV Carriers (male/female) Non carriers (male/female) Effect (male/female) P value
16p11.2 del 14/13 33910/42223 0.14/0.51 1.6 3 10212
22q11.21 dup 25/33 33899/42203 0.60/0.90 0.00093
16p12.1 del 36 76124 1.32 0.0011
15q11.2 del 73/99 33851/42137 0.81/1.03 0.015
1q21.1 del 21 76139 0.76 0.062
15q11.2–13.1 dup 9 76151 0.69 0.11
16p13.1 dup 90 76070 0.91 0.14
16p11.2 distal del 11 76149 0.76 0.2
16p13.1 del 28 76132 0.86 0.22
17q12 dup 28 76132 1.11 0.3
2p16.3 (NRXN1) del 10 76150 0.83 0.34
16p11.2 dup 26 76134 0.89 0.35
22q11.21 del 7 76153 0.79 0.37
17p12 del 24 76136 1.08 0.48
13q31.3 (GPC6) dup 76 76084 0.96 0.55
10q11.22–23 dup 13 76147 1.08 0.62
10q11.22–23 del 12 76148 0.96 0.81
1q21.1 dup 33 76127 1.02 0.88
15q13.1 dup 17 76143 1.02 0.9
2p25.3 (MYT1L) dup 106 76054 0.99 0.91
15q13.3 all del 18 76142 1.01 0.95
Schizophrenia 306/197 33618/42039 0.21/0.54 9.5 3 102206
The effect is the factor by which fecundity is altered in CNV carriers or schizophrenia patients. Different effects onmales and females are shown when there is a significant (P, 0.05) interaction between sex and
either CNV or patient status. Counting both models fitted (with and without sex interaction), 42 tests were performed, thus the significance threshold for CNVs is P50.0012.
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Figure 1 | Association of CNV groups with cognitive traits, GAF, ARHQ
and AMHQ scores. a, Average standardized scores for schizophrenia patients
(n5 161), control carriers of neuropsychiatric CNVs (n5 167), control
carriers of other CNVs (n5 465) and population controls (n5 475).
b, Average standardized scores after adjustment for IQ. AMHQ, adult
mathematical history questionnaire; ARHQ, adult reading history
questionnaire; CF, category fluency; GAF, global assessment of functioning;
LF, letter fluency; LM I and II, logical memory I and II; Pers. errors,
perseverative errors; P IQ, performance IQ; RVIP, rapid visual information
processing; Stroop, difference in time to complete trial 3 and time to complete
trial 2; Stroop 1, Stroop trial 1; SWM, spatial working memory (between-
search errors for 6 boxes); TMT, TMT trail B 2 TMT trail A; TMT A, TMT
trail A; V IQ, verbal IQ; (see Methods for further information on tests). Error
bars represent s.e.m. Impairment is in s.d. units, ARHQ and AMHQ scores for
the patient group are not available.
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Individual neuropsychiatric CNVs
To determine whether the CNVs differ in their effects on cognition,
we examined the association of individual CNVs with neurocognitive
traits, GAF score and history of learning difficulties. Few control car-
riers could be recruited for some of the neuropsychiatric CNVs but
between 5 and 47 control carriers could be evaluated for each of 11
CNVs (Supplementary Table 2). Six of the CNVs are associated with
verbal and/or performance IQ with large effects (0.73–3.51 s.d. units)
in the carrier controls. These are the 16p11.2 deletion and the recip-
rocal duplication, 17p12 deletion, 17q12 duplication, 16p12.1 deletion
and 16p13.1 duplication (Table 2). The effect is also large for the 2p16.3
deletion carriers for performance IQ, although the P value is .0.005
(Supplementary Table 4a). Significant associations were also found
between individual neuropsychiatric CNVs and GAF, spatial working
memory (SWM), AMHQ, category fluency, letter fluency, persevera-
tive errors and Stroop trial 1 (Table 2).
The alleles of the 16p11.2 CNV confer mirrored effects on anthro-
pometric traits13. The deletion, conferring high risk of autism14, shows
the greatest impairments in the cognitive domains tested in the control
carriers. The reciprocal duplication, conferring risk of schizophrenia15
and autism14, confers somewhat different abnormalities on the control
carriers (Supplementary Table 5). Although the deletion is strongly
associated with impaired verbal IQ and deficits in verbal letter and
category fluency tests, in keepingwithwhat is seen in autism, the dupli-
cationmore selectively impairs the spatialworkingmemory and execu-
tive functions that seem to be more important in the pathophysiology
of schizophrenia16.
Four neuropsychiatric CNVs, duplications at 13q31.3, 22q11.21
and 1q21.1 and a deletion at 15q11.2(BP1-BP2), show more modest
(around 0.5 s.d. or less) or no effects on verbal and performance IQ
(Supplementary Table 4a). Twenty-one control subjects carrying the
22q11.21 duplication were evaluated and trends were seen for impair-
ments in all neurocognitive traits and themost significant impairment
was observed in category fluency (0.97 s.d.,P5 1.43 1024) (Supplemen-
taryTable 4a). Tencontrol subjects carrying the1q21.1duplicationwere
evaluated and not even a nominally significant effect was detected on
neurocognitive traits, GAF or history of learning difficulties (Supplemen-
taryTable4a). Forty-sevencontrol subjects carrying the15q11.2(BP1-BP2)
deletionwere evaluated, and significant associationswere observedwith
a lower GAF score (0.66 s.d., P5 9.93 1025), history of learning dif-
ficulties as evaluated by the ARHQ (0.70 s.d., P5 1.93 1024) and the
AMHQ (0.78 s.d., P5 2.3 3 1025) (Supplementary Table 4a). Asso-
ciation with a lower GAF score indicates impaired functioning, pos-
sibly due to some psychological disturbance, although the number of
carriers studiedwas too small to allowdetection of associationwith the
individual phenotypes as derived from the MINI.
When conditioned on IQ the associations with specific cognitive
traits, GAF and history of learning difficulties become less significant
for the 11 CNVs (Table 2 and Supplementary Table 4a). However, the
associationofAMHQscorewith the 15q11.2(BP1-BP2)deletion remains
the most significant (0.70 s.d., P5 2.3 3 1024). In Fig. 2a and Sup-
plementary Table 6 the neuropsychiatric CNVcarriers are divided into
those carrying the 15q11.2(BP1-BP2) and those carrying other neu-
ropsychiatric CNVs. A clear difference in the effect of conditioning the
ARHQ and AMHQ scores on IQ is observed in these two groups: in
the 15q11.2(BP1-BP2) deletion group, the associationwithARHQand
AMHQscores is only slightlyweakenedwhenconditionedonIQ,whereas
in the group of remaining neuropsychiatric CNV carriers (without the
15q11.2(BP1-BP2) deletion carriers) there is no longer any significant
association with the history of learning difficulties after conditioning
on IQ (Fig. 2b and Supplementary Table 6).
The 15q11.2(BP1-BP2) deletion has previously been shown to confer
modest risk of schizophrenia1, behavioural disturbances17, developmental
and language delay18, and epilepsy19. We show that the 15q11.2(BP1-
BP2) deletion has onlymodest impact on results of the neuropsycholo-
gical tests but is still strongly associated with a history of difficulties in
learningmathematics and reading (Fig. 2). IQ is only marginally lower
in the controls carrying the 15q11.2(BP1-BP2) deletion than in the
population controls. Using a score of greater than 0.43 on the ARHQ11
as a surrogate for dyslexia20, the 15q11.2(BP1-BP2) deletion is associated
with dyslexia with an odds ratio of 3.18 (P5 0.0017). Of three previ-
ously describedARHQsubscales, basedon factor analysis11, theARHQ
Table 2 | Controls carrying different neuropsychiatric CNVs perform worse than population controls on cognitive tests, GAF and history of
learning difficulties
CNV Cognitive trait Effect P-value Effect (adjusted for IQ) P-value (adjusted for IQ)
16p11.2 del V IQ 3.51 5.90 3 10216 NA NA
17p12.del V IQ 2.99 2.30 3 1029 NA NA
16p11.2 del LF 2.00 2.00 3 1027 0.61 0.14
16p11.2 del P IQ 2.01 1.30 3 1026 NA NA
16p11.2 del CF 1.83 2.00 3 1026 0.58 0.16
16p11.2 del Stroop 1 1.8 2.80 3 1026 1.14 0.006
16p12.1 del V IQ 2.05 8.30 3 1026 NA NA
16p13.1 dup P IQ 1.09 9.30 3 1026 NA NA
16p11.2 del Pers. errors 1.77 2.00 3 1025 0.48 0.25
15q11.2 del AMHQ 0.78 2.30 3 1025 0.70 0.00023
16p11.2 dup SWM 1.72 3.20 3 1025 1.51 0.00025
17q12 dup GAF 1.63 5.10 3 1025 1.43 0.00037
16p11.2 del GAF 1.55 5.80 3 1025 0.58 0.10
17q12 dup V IQ 1.57 8.10 3 1025 NA NA
15q11.2 del GAF 0.66 9.90 3 1025 0.57 0.0012
16p11.2 del SWM 1.49 0.00011 0.45 0.27
22q11.21 dup CF 0.97 0.00014 0.81 0.0016
15q11.2 del ARHQ 0.7 0.00019 0.60 0.0018
17p12 del GAF 1.67 0.00031 1.11 0.021
16p11.2 del TMT A 1.37 0.0004 0.4 0.33
17p12 del Stroop 1.61 0.00043 1.13 0.018
16p11.2 dup P IQ 1.29 0.00062 NA NA
16p11.2 dup TMT 1.27 0.00073 0.91 0.016
17p12 del CF 1.48 0.0012 0.62 0.2
16p12.1 del P IQ 1.41 0.0021 NA NA
16p13.1 dup V IQ 0.73 0.0022 NA NA
17q12 dup LF 1.2 0.0026 0.78 0.051
16p12.1 del LM I and LM II 1.25 0.0027 0.77 0.092
16p13.1 dup SWM 0.66 0.0049 0.54 0.026
Abbreviations for the different tests are given in the supplementary text. The significance threshold for the 11CNVs each compared for 15 tests and13 IQ-adjusted tests isP50.00016. AMHQ, adultmathematical
history questionnaire; ARHQ, adult reading history questionnaire; CF, category fluency; GAF, general assessment of function scale; LF, letter fluency; LM I and LM II, logicalmemory I and II; NA, not applicable; Pers
errors, perseverative errors; P IQ, performance IQ; Stroop, difference in time to complete trial 3 and time to complete trial 2; Stroop1, Stroop trial 1; SWM, spatial workingmemory; TMTA, TMT trail A; V IQ, verbal IQ.
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dyslexia-symptoms subscale shows the strongest association with the
15q11.2(BP1-BP2) deletion (effect5 0.71 s.d., P5 1.4 3 1024, Sup-
plementary Table 7). Based on a score of greater than 12 on theAMHQ
(see Methods), the 15q11.2(BP1-BP2) deletion shows association with
dyscalculia (odds ratio5 3.91, P5 0.00011). In 136 controls carrying
the reciprocal 15q11.2(BP1-BP2) duplication the results are comparable
to those of population controls on the neurocognitive tests (Supplemen-
tary Table 4a), and their GAF (0.01 s.d., P5 0.95), ARHQ (20.22 s.d.,
P5 0.057) and AMHQ (0.07 s.d., P5 0.52) scores are also in keeping
with those of population controls.
Structural MRI phenotypes
In a search for neural intermediate phenotypes, we performed struc-
tural magnetic resonance imaging (MRI) on 15 control carriers of the
15q11.2(BP1-BP2) deletion, 55 carriers of the reciprocal duplication,
and 201population controls.Given the associationwith schizophrenia,
we focused our attention on regions defined by a recent meta-analysis
of first-episode psychosis21 (Fig. 3a). The 15q11.2(BP1-BP2) deletion
carriers have a reduced volume of greymatter in the perigenual anterior
cingulate cortex (pACC) (Fig. 3b) and the left insula (Fig. 3c). Further-
more, deletion carriers showed reductions in white matter of the tem-
poral lobebilaterally andan increase in the volumeof the corpus callosum
(Fig. 3d). Importantly, for bothgrey andwhitematter, 15q11.2(BP1-BP2)
duplication carriers always show reciprocal changes in exactly the same
regions altered in deletion carriers, providing the first demonstration of
allele-dose-dependent effectsofCNVson the structureof thehumanbrain.
The pACC is a key region for regulation of limbic activity22 previously
shown to be abnormal in schizophrenia23. Furthermore, the frontoin-
sular cortex is highly connected to the pACC, with which it forms the
cortical aspects of the salience network24, a circuitry linked to schizo-
phrenia risk25. Although reduction in the volume of the temporal lobe
white matter is a well-established feature of schizophrenia and is pre-
sent early in the illness26, the finding of increased callosal volume was
unexpected, as patientswith schizophrenia have reduced volume in this
region27. Notably, carriers of the schizophrenia-associated 22q11.21
deletion also show increased volume of the corpus callosum28.
The abnormalities found in the structural MRI studies also show
overlap with published work on structural correlates of dyslexia and
dyscalculia. In dyslexia, grey matter abnormalities in the supramar-
ginal gyrus were prominent in a recent meta-analysis29. Grey matter
reductions in a very similar location in pACC have also been seen in
developmental dyscalculia30. In both cognitive developmental disor-
ders, other regions are abnormal that are not implicated in the present
study (suchas left perisylvian areas indyslexia and the intraparietal sulcus
in dyscalculia), suggesting that the neuropsychological impairment seen
in 15q11.2(BP1-BP2) deletion carriers may be related to specific key
nodes in the networks associated with these cognitive dysfunctions.
It is of interest that the controls carrying the 15q11.2(BP1-BP2)
duplication (n5 136) perform to a similar level as population controls
on all tests of cognitive function used in this study (Supplementary
Table 4a). Thus, although mirror effects on brain volume phenotypes
are observed for the 15q11.2(BP1-BP2) CNV, we do not observe clear
mirror effects on the ARHQ and AMHQ scores.
Conclusion
There were two main aims to this study. The first was to determine
whether carriers of CNVs that predispose to schizophrenia and/or
autism,whohavenotbeendiagnosedwithapsychoticdisorderor autism,
have cognitive abnormalities that are akin to those encountered in schizo-
phrenia. If this were the case these neuropsychiatric CNVs could be
used as instruments in the study of cognitive abnormalities that char-
acterize the disease. The results show that carriers of these CNVs show
cognitive abilities in between those of normal controls andpatientswith
schizophrenia. This raises the possibility that the difference between the
patients and the control carriers may not be due to a lack of penetrance
but instead to variation in expressivity of the CNVs. It also shows that
the cognitive abnormalities are not necessarily consequences of the
disease, and that the risk of the diseasemay, at least in part, bemediated
through the cognitive abnormalities. These CNVs could be used to iden-
tify individuals inwhomschizophrenia-like cognitive abnormalities could
be studiedwithout the confounding effects of psychosis ormedications.
The second aim was to better define the cognitive abnormalities in
population controls carryingCNVs associating with schizophrenia and
autism; by evaluating controls carrying the neuropsychiatric CNVs we
sought to learn more precisely which cognitive abnormalities put car-
riers at risk of developing schizophrenia. We tested the carriers prim-
arily for those aspects of cognition that have been shown to be abnormal
in schizophrenia (Fig. 1), and in all of these aspects the control carriers
were found to perform somewhere between the schizophrenia patients
and the population controls. When controlled for IQ, the number of
tests that separate the control neuropsychiatric CNV carriers from
population controls decreases substantially, which is not surprising
as these tests assess functions that are components of the IQ. Of the
Population controls
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Figure 2 | Association of CNVs with cognitive traits, GAF, ARHQ and
AMHQ scores. a, Average standardized scores for controls carrying
neuropsychiatric CNVs excluding the 15q11.2(BP1-BP2) deletion carriers
(blue,n5 120), controls carrying the15q11.2(BP1-BP2) deletion (cyan,n5 47)
and population controls (black, n5 475). b, Average standardized scores
conditioned on IQ. Error bars represent s.e.m.
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11 neuropsychiatric CNV alleles tested independently for association
in 5 or more controls, 8 associated with a cognitive trait.
Dosage-sensitive genes at CNV loci can give rise to mirrored phe-
notypes for anthropometric loci including bodymass index13 and head
circumference15. In this study we provide the first evidence that dose-
dependent effects ofCNVsalso affect humanbrain structure directly.Two
brain regions,with clear evidenceof both structural and functional altera-
tions early in the courseof schizophrenia, showdosage effects in controls
carrying the 15q11.2(BP1-BP2) deletion and its reciprocal duplication.
In this paperwedemonstrate how cognitive abnormalities and changes
in the structure of the brain observed in schizophrenia are also found in
control carriers of CNVs that confer high risk of the disease. One of the
missing pieces in our understanding of the pathogenesis of schizophre-
nia has been the nature of the physiologic function that is first per-
turbed in the disease or the perturbation of which leads to the disease.
We show that carriers who have not been diagnosed with autism, intel-
lectual disability, or schizophrenia show intermediate phenotypes in
brain structure that are in good agreement with the observations in
first-episode psychosis. We suggest that the work presented here lends
support to the idea that the cognitive abnormalities are fundamental
defects in schizophrenia as they are manifest in carriers of CNVs confer-
ring risk of the disease who do not suffer from the disease. Furthermore,
in addition to the information theymay provide ondisease, theseCNVs
provide us with an opportunity to search systematically for the bio-
chemical foundations of the cognitive differences between the carrier
and non-carrier controls.
METHODS SUMMARY
Control subjects carrying CNVs or not carrying CNVs were recruited from a
large genotyped sample. Subjects aged 18 to 65 years were recruited for cognitive
phenotyping. The psychologists and psychiatrists evaluating all subjects were
blind to genotype. To examine fecundity, a nation-wide genealogy database
was used to calculate fecundity of patients and controls carrying neuropsychiatric
CNVs. The MINI5 was used to screen the controls for psychiatric disorders, and
participants’ overall level of functioning and their ability to carry out activities of
daily living were rated using the GAF scale31. Memory was assessed using the
logical memory subtest from Wechsler Memory Scale III (WMS-III)32. Verbal
fluency was assessed using the controlled oral word association test (COWAT)33
and the category naming test34. The Stroop test was administered as an indicator
of the ability to suppress an habitual response35. The trail-making test (TMT) was
administered as a measure of psychomotor speed and mental flexibility36. As a
further measure of mental flexibility, including the ability to alter cognitive sets,
the Wisconsin card sorting test (WCST)37 was administered and the ratio of
perseverative errors to the number of trials administered used in our analysis.
Spatial working memory and sustained attention were evaluated by the compu-
terized CANTAB battery, using the SWM38 and rapid visual information pro-
cessing (RVIP) subtests39, respectively. Intelligence was evaluated using the
Wechsler Abbreviated Scale of Intelligence (WASI-I)40. For neuroimaging, MRI
examinations were conducted on a 1.5 T whole body Philips Achieva scanner.
High-resolution T1-weighted images were processed according to the unified
segmentation model with SPM8 and Matlab 8b software. Copy-number effects
were examined on a voxel-by-voxel basis with a multiple regression model using
SPM8.
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METHODS
Control subjects carrying or not carrying CNVs were recruited from a large
genotyped sample. Subjects aged between 18 and 65 years were recruited for
cognitive phenotyping. The psychologists evaluating all subjects were blind to
genotype. A nation-wide genealogy database was used to calculate the fecundity
of patients and controls carrying neuropsychiatric CNVs. The mini international
neuropsychiatric interview (MINI)5 was used to screen the controls for psychi-
atric disorders, and participants’ overall level of functioning and their ability to
carry out activities of daily living were rated using the general assessment of
function (GAF) Scale31. Memory was assessed using the logical memory subtest
fromWechsler Memory Scale III (WMS-III)32. Verbal fluency was assessed using
the controlled oral word association test (COWAT)33 and the category naming
test34. The Stroop test was administered as an indicator of the ability to suppress
an habitual response35. The trail-making test (TMT) was administered as a mea-
sure of psychomotor speed andmental flexibility36. As a furthermeasure ofmental
flexibility, including the ability to alter cognitive sets, the Wisconsin card-sorting
test (WCST)37was administered and the ratio of perseverative errors to the number
of trials administered used in our analysis. Spatial workingmemory and sustained
attention were evaluated by the computerized CANTAB battery, using the spatial
workingmemory (SWM)38 and rapidvisual informationprocessing (RVP) subtests39,
respectively. Intelligence was evaluated using the Wechsler Abbreviated Scale of
Intelligence (WASI-I)40. For neuroimaging,MRI examinationswere conducted on
a 1.5 T whole body Philips Achieva scanner. High-resolution T1-weighted images
were processed according to the unified segmentation model with SPM8 and
Matlab 8b software. Copy number effects were examined on a voxel-by-voxel basis
with a multiple-regression model using SPM8.
Sample. Twenty-six CNVs conferring risk of psychiatric disorders (‘neuropsy-
chiatric CNVs’), of which most are recurrent, were identified through literature
search (SupplementaryTable 1).Control subjects carryingneuropsychiatricCNVs
were identified froma large genotyped sample (n5 101,655). The sample had been
genotyped by Illumina HumanHap (300, 370, 610, 1M, 2.5M) and Illumina Omni
(670, 1M, 2.5M, Express) SNP arrays. BeadStudio (Illumina; version 2.0) was used
to call genotypes, normalize signal intensity data and establish the logR ratio andB
allele frequency at every SNP. Samples passing quality control were examined
using PennCNV41. All putative neuropsychiatric CNVs and other CNVs not
known to be associated with schizophrenia or autism (‘other CNVs’) were visually
inspected using DosageMiner software (developed by deCODE genetics). The
neuropsychiatric CNVs, with one exception, span more than 15 SNPs on the
Illumina arrays (Supplementary Table 1).
Both the neuropsychiatric CNVs and the other CNVs are large, on average
around 1.5 and 1.0 Mb, respectively. All 26 neuropsychiatric CNVs delete or
duplicate exons of genes, whereas 89 of the 94 other CNVs delete or duplicate
exons of genes (Supplementary Table 8).
In the sample of 101,655 genotyped subjects we identified 1,178 subjects car-
rying one or more of the neuropsychiatric CNVs (1.16% of the sample). Carriers
aged between 18 and 65were recruited for further phenotyping andwere excluded
from control groups if any of the following applied: if they were diagnosed with
schizophrenia, schizoaffective or bipolar disorder; if they were diagnosed with
autism, intellectual disability or developmental delay at the State Diagnostic and
Counseling Centre in Iceland serving children and adolescents with a disability; if
they met psychoses criteria on the MINI interview; if they were diagnosed with
schizophrenia, schizoaffective, bipolar disorder, autism, intellectual disability or
developmental delay according to self reports (or reports from parents); if they
were using antipsychotic drugs.
Phenotyped control subjects passing the exclusion criteria were: 167 controls
carrying neuropsychiatric CNVs; 465 controls carrying otherCNVs: 475 controls
without large CNVs. In addition, 161 schizophrenia patients were recruited for
the neuropsychological phenotyping.
Phenotyping. Encrypted identifiers of subjects were decrypted by a represent-
ative of the IcelandicData ProtectionAuthority and subjects were recruited to the
study by a clinic overseen by the IcelandicData ProtectionAuthority. Psychologists
and nurses phenotyping the participants were blind to genotype. Those working
with the genetic data were blind to personal identifiers and could only work on the
encrypted data set. Only a representative of the Data Protection Authority of
Iceland holds the key for encrypting and decrypting the personal identifiers.
Genotypes are only linked to encrypted identifiers. Approval for this study was
obtained from theNational Bioethics Committee of Iceland and the IcelandicData
Protection Authority. Written informed consent was obtained from all partici-
pants or their guardians before blood samples or phenotypic data were obtained.
All sample identifiers were encrypted in accordance with the regulations of the
Icelandic Data Protection Authority.
GAF42 score was used to rate participants overall level of functioning and their
ability to carry out activities of daily living. The scale was rated by the tester with
respect to psychosocial, social, and occupational functioning. All participants
were also interviewed using the MINI5 edition 5.0.0. The MINI was designed as
a brief structured interview for the major Axis I psychiatric disorders in ICD-10
and DSM-IV.
Toassess cognitive function, logicalmemory I and II from theWechslerMemory
Scale (3rd edn) (WMS-III)32 was used to assess memory. An Icelandic translation
of the test was used (unstandardized). Two variables from the test were calculated;
immediate memory that is the total item score immediately after the reading of
story A and after both readings of story B, and delayed memory that is the total
item score from both stories after 30 min delay. The average of the two scores was
used in the analysis.
Verbal fluency was assessed using the COWAT33 and the category naming
test34; animal naming. In COWAT the subject is required to name as many words
as he or she can that begin with a certain letter in one minute, the letters H and S
were used in the Icelandic translation (unpublished). For the analysis a mean
score of the number of words registered with each of the two letters were calcu-
lated (verbal fluency) and for category fluency the number of animals registered
(category fluency).
The Stroop test35 is a measure of selective attention and the ability to block out
irrelevant stimuli. An Icelandic translation (unpublished), derived from the
Golden version43, was used in this study. In the first trial the participant is asked
to read the names of colours written in black ink. In the second trial the particip-
ant has to name the colour of words written in coloured ink, and in the last (the
main) trial the participant has to name the colour of the ink of a word which is
actually the name of another colour. Twomeasures from the Stroop test were used
in the analysis; the time it took to finish trial 1, and the interference score which is
the difference in time to complete trial 3 minus the time for completing trial 2.
For visual scanning and mental flexibility, TMT A and B36 were used adminis-
tered. Trail A is a measure of psychomotor speed and attention and trail B is
thought to be a test of flexibility of thinking. Ameasure of the time it took to finish
trail A and a derived score of the time it took to finish trail B minus trail A was
used in the analysis.
The WCST was designed to assess abstract reasoning and the ability to shift
cognitive strategies in response to environmental cues37. A computerized version
of the test was used44. The variable used in our analysis is per cent perseverative
errors, which reflects the ratio of perseverative errors to the number of trials
administered. Perseverative errors aremade when participant persists in respond-
ing to the old rule after the rule has changed.
The SWM subtest from the CANTAB battery was used, which gives a measure
of spatial working memory38. The measure used in this analysis was between-
search errors for 6 boxes,which is a count of times the subject revisits a box where
the token has previously been found. This is thought to rely on the long-term
spatial memory system as the subject has to remember the location for some time
and through interferences45.
RVIP, a subtest from the CANTAB battery was used to access vigilance, which
is the ability to sustain attention on one ormore items over a period of time39. The
main variable is A9, which is a signal detection measure of sensitivity to errors
regardless of error tendency. This is a measure of the subjects ability to detect
target sequences by using p(hit) and p(false). p(hit) is the probability of a hit; the
proportion of correct responses that are givenwhen a target sequence is presented
on the screen. p(false) is the probability of a false alarm; the proportion of res-
ponses when there is no target sequence presented on the screen.
Intelligence quotient (IQ) was assessed using the WASI-I. The WASI-I test
includes four subtests: vocabulary and similarities, both tests of verbal IQ, and
matrix reasoning and block design, both tests of performance IQ40.
TheWASI-I test has been translated into Icelandic for standardization that is in
progress and this study has been a part of that work. Here the healthy control
group was used to make local norms by calculating the mean and s.d. for each of
the age groups used in the US version of the WASI-I. Z-scores were then calcu-
lated for every subtest for each participant, and the mean of the subtests was
transformed into an IQ score having a mean of 100 and a s.d. of 15 in the healthy
control group.
A fraction of the participants were tested with an older translation of the
WASI-I with two subtests, vocabulary andmatrix reasoning. Thirty-nine subjects
were tested using both editions of the test (with more than one year apart), and
Pearson’s correlation coefficient between the two measures in these subjects was
0.66. No significant effect of test type (new or old translation of WASI-I version)
was found in any group included in the study.
The adult mathematical history questionnaire (AMHQ) described here is
modelled after the adult reading history questionnaire (ARHQ)12. The AMHQ
consists of six questions, each scored on a Likert-type scale ranging from 0 to 4.
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The questions were: 1. Did you experience any difficulties in learning math in
elementary school? 2. How was your math performance compared to your class-
mates in elementary school? 3. How do you rate your math skills now compared
to people your age with a comparable education level? 4. Did you experience any
difficulties learning the multiplication table in elementary school? 5. How much
extra help did you needwhen learningmath in elementary school? 6.What is your
current attitude towards math?
The six questions were selected to assess the degree to which adults have experi-
enced symptoms of specific disorder of arithmetical skills, or dyscalculia (F81.2),
which according to the ICD-10 criteria20, ‘‘Involves a specific impairment in arith-
metical skills that is not solely explicable on the basis of general mental retardation
or of inadequate schooling. The deficit concerns mastery of basic computational
skills of addition, subtraction, multiplication, and division rather than of the more
abstractmathematical skills involved in algebra, trigonometry, geometry, or calculus.’’
The score for the AMHQ scale ranges from 0 to 24 with higher scores indi-
cating greater impairment. Internal consistency reliability (a5 0.90)was assessed
using Cronbach’s a from AMHQ results of a large survey sample (n5 2,757). An
exploratory factor analysis of this data set combining 28 items from ARHQ-Ice
(22) and AMHQ (6) found that association with all three previously reported
ARHQsubscale factors (dyslexic symptoms, current reading andmemory)11 were
replicated, and all sixAMHQ itemshad high factor loadings ($ 0.55) on a separate
fourth factor. This further confirms the internal consistency of the AMHQ scale
and suggests an independence of the arithmetical disorder scale from the ARHQ
total scale representing specific reading disorder or dyslexia and its three subscales11.
Concurrent validity was assessed by comparing AMHQ scores of adults (n5 39)
whohad by formal neuropsychological evaluation been diagnosed as childrenwith
specific disorder of arithmetical skills (F81.2) and population controls without
diagnosis of psychiatric or learning disorders and no learning disorder by self-
report (n5 564). A significant difference inmean AMHQ scores was observed for
these groups; that is, 17.8 (s.d.5 6.5) and 8.1 (s.d.5 5.3), respectively (P, 0.001).
For statistical analysis of cognitive traits, scores from each cognitive test or
questionnaire were inverse normally transformed. They were then adjusted for
sex, age at testing and, where indicated, IQ based on data from controls only. Final
scores were shifted and scaled so that controls had a mean of 0 and a standard
deviation of 1, and also arranged so that higher scores indicated greater impair-
ment. To take the information on relatedness of the individuals into account,
CNV carriers or schizophrenia patients were compared with controls using gen-
eralized least-squares regression with a variance–covariance matrix based on the
kinship coefficient of each pair of individuals. Meiotic distance between neurop-
sychiatric CNV control carriers evaluated for cognitive traits can be found in Sup-
plementary Table 4b.
The sample sizes obtained resulted in about 80% power to detect a difference of
around 0.4 s.d. in the neuropsychiatric CNV control or schizophrenia versus popu-
lation control comparisons, and about the same amount of power to detect a
difference of around 0.3 s.d. for the other CNV control versus population control
comparison. For the individual neuropsychiatric CNVs with the smallest sample
size (n55), therewas approximately 80%power to detect a difference of about 2.5 s.d.
Fecundity. deCODE genetics has built a nation-wide genealogy database for its
genetic studies. The database contains information on year of birth and numbers
of children of Icelanders. An encrypted version of the genealogy database was
used for studying the fecundity in patient and CNV groups.
Mixed-effects Poisson generalized linearmodels (GLMs) were used to examine
the association of fecundity with various neuropsychiatric CNVs and schizophre-
nia. The number of children at age 45 or older was regressed on sex, year of birth
(included as factors for each 5 year birth cohort), sex-year of birth interaction (for
each birth cohort factor), sibship (to account for relatedness) and the CNV or
disorder of interest. All predictors weremodelled as fixed effects except for sibship,
which was random. A second set of models including a sex-CNV/disorder inter-
action term were also fit.
Neuroimaging.MRI examinationswere conducted on a 1.5 Twhole body Philips
Achieva scanner. Scans were performed with a sagittal 3D fast T1-weighted
gradient echo sequence (TR 8.6ms, TE 4.0ms, flip angle 8 degrees, slice thickness
1.2 mm, matrix 1923 192, field of view 2403 240 mm). Quality control of the
MRI images consisted of a test of image homogeneity covariance andnoise estima-
tion (VBM8 toolbox; Gaser, http://dbm.neuro.uni-jena.de/author/admin/) as well
as visual inspection.
For voxel-basedmorphometry, high-resolution T1-weighted images were pro-
cessed according to the unified segmentation model46 with SPM8 (statistical
parametricmapping,WellcomeDepartment of CognitiveNeurology http://www.
fil.ion.ucl.ac.uk/spm) and Matlab 8b software (The Mathworks). In brief, this
method involves an iterated scheme of bias correction, segmentation into white
matter, grey matter and cerebrospinal fluid and warping of prior images in ste-
reotactic space to the data, which is repeated until no significant change occurs
anymore. During normalization, images were interpolated to isotropic 13 13 1
mm voxels. The VBM8-toolbox extends this model with a partial volume estima-
tion to account for partial volume effects and the application of a spatially adaptive
non-local means (SANLM) filter47 for bias correction. Normalization to stereo-
tactic space consisted of a linear affine registration and a linear deformation cor-
responding to a high-dimensional DARTEL normalization48 implemented in
VBM8.The resultingprobabilitymapsweremodulated, that is, intensity-corrected
for local volume changes duringnormalization, tomake themmore sensitive to the
distribution of grey matter and white matter volume. Modulation was limited to
nonlinear warping; global differences in brain volume were thus excluded in the
modulated probability maps. The modulated maps were smoothed with a 12-mm
FWHM kernel.
For statistical analysis of neuroimaging data from MRI subjects carrying the
15q11.2(BP1-BP2) CNV, copy number effects at 15q11.2 (duplication. control
. deletion and deletion. control. duplication) on regional brain volume were
examined on a voxel-by-voxel basis with amultiple regressionmodel using SPM8;
age and gender were included as covariates of no interest.
An interaction between performance on neuropsychological tests that indi-
cated a genetic dosage effect and copy number at 15q11.2, on regional greymatter
volume was tested with a multiple regression analysis (SPM8); age and gender
were included as covariates of no interest.
Effects on grey matter volume were reported as significant when whole-brain
voxel-level FWE-correctedP value was less than 0.05. Additional region-of-interest
(ROI) analyses were performed in the following regions found to show both func-
tional and structural abnormalities in a recent meta-analysis of subjects with high
risk of schizophrenia21: anterior cingulate and medial frontal cortex, and bilateral
insula extending into temporal and parietal cortex. Results of these ROI analysis
were considered significant at P, 0.05 voxel level, FWE-corrected.
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